Founder H Fund is a financial investment management institution that provides direct investment services.
Founder H Fund Co. Ltd., a wholly-owned subsidiary of Founder Securities Co. Ltd., is a professional financial investment management institution that has been committed to providing direct investment services. It is approved by the China Securities Regulatory Commission, and ranks among the Top 10 PE Subsidized by Securities Companies in China. The core team has more than 10 years’ experience in equity investments, mergers and acquisitions, cross-border investments and mezzanine investments in the capital market. Founder H Fund strives to maximize the competitive edge of its team, promote industrial upgrading in China and help companies achieve sustainable development.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 7, 2022
XellSmart
|
Series A | — | Biopharma | — |
May 27, 2022
HemaCell
|
Series A | — | Biotechnology | — |
Jul 1, 2021
Sirnaomics
|
Series E | $105M | Biopharma | — |
Apr 29, 2020
Mabwell Biotech
|
Series A | $278.50M | Biopharma | — |